Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

Madrigal Pharmaceuticals Inc. has demonstrated significant therapeutic efficacy of its drug, Rezdiffra, by successfully shifting approximately two-thirds of patients with Cirrhotic Severe Portal Hypertension (CSPH) to lower risk scores, indicating its potential impact on liver health. The company has also observed stronger-than-expected real-world adherence and refill trends, showcasing the quality of life benefits experienced by patients during long-term treatment, which further enhances the drug's market viability. Additionally, increased penetration estimates in the F2/F3 patient categories, alongside new revenue projections of $7.1 billion by 2035, reinforce Madrigal's positive growth trajectory in the biopharmaceutical sector.

Madrigal Pharmaceuticals Inc faces significant risks that could adversely impact its financial outlook, primarily due to potential lower-than-expected peak sales stemming from competition and inadequate support from healthcare providers and payers. The company anticipates a slight reduction in revenue for 1Q26, which will be exacerbated by first-quarter dynamics and increased gross-to-net pressures due to revised contracting terms. Furthermore, key risks include potential FDA and EMA approval failures, possible clinical trial setbacks in their Outcomes study, and unanticipated competitive threats, all of which could hinder operational funding and growth prospects.